Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00319969 · ClinicalTrials.gov registry record · Phase 2
Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.
A Phase 2 study of Small-cell Lung Cancer, sponsored by Celgene Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 20
- Study locations
NCT00319969: Completed Phase 2 study of Small-cell Lung Cancer, sponsored by Celgene Corporation.
NCT00319969 is a Phase 2 study of Small-cell Lung Cancer that has completed, run by Celgene Corporation. The registered enrollment target is 76 participants, below the 231-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00319969, a Phase 2 study of Small-cell Lung Cancer, has completed, sponsored by Celgene Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the objective tumor response rate of amrubicin or standard topotecan therapy when administered as second-line therapy to ED-SCLC patients who have chemotherapy sensitive recurrent or progressive.
Conditions Studied
Interventions
- DRUG Topotecan
- DRUG Amrubicin
Study Locations (20)
Maryland
- Sinai Hospital of Baltimore - Baltimore
- Johns Hopkins Hospital - The Bunting Blaustein Cancer Research Building - Baltimore
- Maryland Oncology Hematology, PA - Columbia
- Alliance Hematology Oncology, PA - Carroll County Cancer Center - Westminster
Illinois
- Cancer Care & Hematology Specialists of Chicago - Niles
- Oncology & Hematology of Central Illinois - Peoria
- Blessing Cancer Center - Quincy
California
- Alta Bates Medical Center - Comprehensive Cancer Center - Berkeley
- Moores UCSD Cancer Center - La Jolla
Colorado
- Rocky Mountain Cancer Center - Denver - Denver
- Rocky Mountain Cancer Center - Sky Ridge - Lone Tree
Florida
- Ocala Oncology Center - Ocala
- Cancer Centers of Florida, PA - Ocoee
Indiana
- Central Indiana Cancer Centers - Indianapolis
- Hope Center - Terre Haute
Alabama
- Birmingham Hematology & Oncology - Birmingham
Arizona
- Hematology Oncology Associates - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
What the finished NCT00319969 record still lists
NCT00319969 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 231-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Topotecan is the first listed.
NCT00319969 names 20 study sites across 11 states, led by Maryland, Illinois, California.
Frequently Asked Questions
What is clinical trial NCT00319969 about?
NCT00319969 is a clinical study titled "Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.". The purpose of the study is to evaluate the objective tumor response rate of amrubicin or standard topotecan therapy when administered as second-line therapy to ED-SCLC patients who have chemotherapy sensitive recurrent or progressive.
What is the current status of trial NCT00319969?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2006-04. Estimated completion is 2009-01.
What conditions does trial NCT00319969 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT00319969?
The interventions under investigation include: Topotecan (DRUG), Amrubicin (DRUG).
Who is sponsoring clinical trial NCT00319969?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00319969 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00319969's enrollment target sits among peer trials
76 41st of 79 higher than 39 of 79 other Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
RECRUITING · Phase 2
-
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
RECRUITING · Phase 2
-
Study of Trilaciclib and Lurbinectidin
RECRUITING · Phase 2
-
Phase 2 Study of Fingolimod in Lung Cancers
RECRUITING · Phase 2
-
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
RECRUITING · Phase 2
-
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia